Bayer flags new blood thinner as $5 bln-plus opportunity

Bayer flags new blood thinner as $5 bln-plus opportunity The first revenue outlook for asundexian, designed to prevent thrombosis and strokes, shows Bayer's confidence that it can replace revenue from one of its pharmaceutical best-sellers, Xarelto, which is set to lose protection from key European patents in 2026. https://ift.tt/KgrPDfU